The first patient has enrolled in the Phase I clinical trial and was dosed on Sunday, April 14. No acute safety issues were reported.

Tenboron’s background and BNCT technology are presented in this post:

https://www.suomenbioteollisuus.fi/post/finnish-company-tenboron-develops-groundbreaking-cancer-treatment

Study preparations have been completed and necessary permits obtained.

Data from the first patient(s) expected in Q1/2024.

Tenboron is a showcase company in this year’s LSX Nordic Congress which takes place in Copenhagen, Denmark on October 10-11.

The Finnish Medicines Agency Fimea has approved Tenboron’s Phase I clinical trial application.
The study will be conducted at the Helsinki University Hospital.
Preparations for study initiation are underway.